P/B
4,6
Humacyte
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
$143.8M
Market Cap • 9/30/2026
2020
(6 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
67,8
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,1
EPS
—
Market Cap
Market Cap
143,8M
EV
130,1M
EV/Revenue
61,3
EV/EBITDA
-1,3
EV/EBIT
-1,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-97,2%
Total Yield
-97,2%
Payout
0%
Retained Earnings
-781,3M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
3276%
Capex/Revenue
17,3%
Capex/D&A
5,1%
Capex/OCF
-0,4%
SBC/OCF
—
% PPE
32,2%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
2,4%
CAGR Op. Income 5Y
9,1%
CAGR Net Income 5Y
6,8%
CAGR EPS 5Y
-47,5%
CAGR OCF 5Y
9,2%
Leverage
N.D./EBITDA
0,1
Debt/Equity
0%
Current Ratio
6,2
Quick Ratio
5,4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!